Active — Not RecruitingNot Applicable

Chronic Kidney Disease Registry Platform Study

China5,000 participantsStarted 2023-11-28

Plain-language summary

This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical characteristics, diagnostic and treatment patterns, and clinical outcomes of patients with chronic kidney disease (CKD), to describe the current status of the diagnosis and treatment of patients with CKD and the gaps from the diagnostic and treatment guidelines, explore the risk factors for disease progression and clinical outcomes in CKD patients, and construct a risk prediction model for CKD progression and clinical outcomes

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Aged ≥ 18 years at enrollment;
✕. Patients who meet the diagnostic criteria for CKD;
✕. Last eGFR ≥ 20 and \< 90 mL/min/1.73 m2 (with the CKD-EPI formula) within 12 months prior to enrollment;
✕. Patients who voluntarily participate in this study and has signed and dated the informed consent form for the study;
✕. Patients who have previously undergone/are undergoing/are planning to undergo solid organ transplantation;
✕. Patients with active malignant tumor requiring drug therapy at the time of screening;
✕. Women who are pregnant, planning to become pregnant or who are breastfeeding.
✕. Patients with NYHA class III or IV heart failure at screening;

What they're measuring

Disease Progression in CKD Patients

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Renal Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Cardiovascular Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Cardiac and Renal Composite Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - All-cause Mortality

Timeframe: From 2023 to 2027

Changes in Patient Conditions - Changes in Proteinuria

Timeframe: From 2023 to 2027

Estimates of Changes in Patient Conditions - Changes in eGFR

Timeframe: From 2023 to 2027

Trial details

NCT IDNCT06117852

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-11-30

View on ClinicalTrials.gov More Chronic Kidney Diseases trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Aged ≥ 18 years at enrollment;
✕. Patients who meet the diagnostic criteria for CKD;
✕. Last eGFR ≥ 20 and \< 90 mL/min/1.73 m2 (with the CKD-EPI formula) within 12 months prior to enrollment;
✕. Patients who voluntarily participate in this study and has signed and dated the informed consent form for the study;
✕. Patients who have previously undergone/are undergoing/are planning to undergo solid organ transplantation;
✕. Patients with active malignant tumor requiring drug therapy at the time of screening;
✕. Women who are pregnant, planning to become pregnant or who are breastfeeding.
✕. Patients with NYHA class III or IV heart failure at screening;

What they're measuring

Disease Progression in CKD Patients

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Renal Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Cardiovascular Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - Cardiac and Renal Composite Outcomes

Timeframe: From 2023 to 2027

Clinical Outcomes in CKD Patients - All-cause Mortality

Timeframe: From 2023 to 2027

Changes in Patient Conditions - Changes in Proteinuria

Timeframe: From 2023 to 2027

Estimates of Changes in Patient Conditions - Changes in eGFR

Timeframe: From 2023 to 2027